Cellectis (CLLS) Reports Q2 Loss of EUR0.23/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to Cellectis (CLLS) Reports Q2 Loss of EUR0.23/Share

Cellectis Reports 2nd Quarter and First Half Year 2016 Financial Results

September 8, 2016 5:31 PM EDT

- First patient dosed in phase 1 clinical trial for UCART19

- UCART 123 manufacturing ongoing

- Strong cash position of $300 million1 (270 million) as of June 30, 2016

- Revenues and other income of $20 million2 (18 million) in the 2nd quarter of 2016

- Adjusted income attributable to shareholders3 of $9 million2 (8 million) in the 2nd quarter of 2016

NEW YORK--(BUSINESS WIRE)-- Regulatory News:

Cellectis S.A. (Paris: ALCLS) (NASDAQ: CLLS) (Alternext: ALCLS - Nasdaq: CLLS), a... More